

17 April 2020

Marc Salit,
JIMB Director

SLAC National
Lab and Stanford
University

Coronavirus Standards Working Group

What should a Coronavirus Standards Working Group do?



Assure development and availability of standards, controls, interlab testing, knowledge to support successful rollout & scaling of 2019-nCoV testing



Identify and develop critical infrastructure to support...

- confidence in test results
- interoperability
- scale-up
- long-term capacity



Identify best practices that should be institutionalized

Learn what we need to so next time we have a global network in place ready to make standards.

The background of the slide features three white Erlenmeyer flasks filled with a blue liquid. The flasks are arranged in a row, with the one on the right being the most prominent. The number '200' is visible on the side of the middle and right flasks. In the foreground, a large, detailed 3D model of a coronavirus particle is superimposed over the flasks. The particle has a grey, textured core and is covered in red, crown-like spikes. There are also some small orange and yellow dots scattered on the surface of the particle.

17 April Agenda


- Manuscript update
- Communications Strategy update
- Early results from comparisons
 - Heinz Zeichardt, IQVD GmbH
 - INSTAND EQAS 340
 - Alex Marson, UCSF
 - Serological Benchmarking

Manuscript Update

“We are working together to make sure that the standards, controls, validation tests, and protocols are in place so we can count on test results.

Our work is foundational, and upstream of the existing mechanisms that establish reliability and trustworthiness of results in the diagnostic sector, including regulatory oversight.

This report describes our systematic consideration of the measurement process and how different standards play roles throughout it.”



Join drafting team, 1400PDT today

Communications Strategy Update

Follow-up from Last Week

- Compiling list of communications avenues
- Considered name
 - Standardization
 - International
 - Global
 - “Working Group” – implies action
 - Acronyms
 - Scope
 - “Emerging virus...”
 - “COVID”

Near-term Plans

- Develop and roll out preprint
- Coordinate network of communications from the WG
 - provide high-level messaging about the WG and the findings in the preprint
 - use all member’s audiences, channels, vernaculars
 - develop FAQs
 - press/media outreach (Nature, GenomeWeb, quality news papers,...)

Early results from an interlab study

Prof. Dr. Heinz Zeichhardt
IQVD GmbH
Institut für Qualitätssicherung in
der Virusdiagnostik
Berlin



IN STAND e. V.

Gesellschaft zur Förderung der Qualitätssicherung
in medizinischen Laboratorien e. V.
(vormals Hämometerprüfstelle)

In cooperation with
Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV)
Gesellschaft für Virologie (GfV)
Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM)



IN STAND-Geschäftsstelle
Ubierstr. 20
D-40223 Düsseldorf
Telefon: +49 (0)211 1592 13 0
Fax: +49 (0)211 1592 1330
E-mail: instand@instand-ev.de
Web: www.instand-ev.de

23 March 2020

Extra IN STAND EQAS –Virus Genome Detection (340)

Coronavirus SARS-CoV-2

Deadline for registration: Sunday, 29 March 2020
Shipment: Friday, 03 April 2020
Deadline for receipt of data: Wednesday, 22 April 2020

Dear colleagues,

Referring to our information of 14 February 2020, IN STAND e.V. wants to inform you on the organizational changes in regard to the EQA scheme for virus genome detection of coronaviruses.

Due to the new epidemiological situation with SARS-CoV-2, IN STAND e.V. in its capacity as reference institution of the German Medical Association as EQA provider will change the EQA schemes for virus genome detection of coronaviruses

Ringversuchsleiter:
Univ.-Prof. i.R. Dr. Heinz Zeichhardt
Charité - Universitätsmedizin Berlin

Korrespondenzadresse:
Prof. Dr. Heinz Zeichhardt
Institut für Qualitätssicherung
in der Virusdiagnostik - IQVD GmbH
Potsdamer Chaussee 80
14129 Berlin
Telefon: +49-(0)30-81054-300
Fax: +49-(0)30-81054-303
Email: Heinz.Zeichhardt@iqvd.de

Stellv. Ringversuchsleiter:
Dr. Martin Kammel
c/o IN STAND e.V.
Ubierstr. 20,
40223 Düsseldorf
Telefon: +49-(0)30-81054-300
Fax: +49-(0)30-81054-303
Email: m.kammel@iqvd.de

Alex Marson

Associate Professor, UCSF
Scientific Director of
Biomedicine, Innovative
Genomics Institute (IGI)
Chan Zuckerberg Biohub
Investigator

Early results from a
serological test
comparison

Compare a large population of
serological tests using a well-
designed panel of ~300 patient
samples

All other business

Mailing list – converting to Google Groups (MailChimp too much work)

Communications, planning, engagement, process, operations?

Discussion